NATCO Pharma Ltd on Tuesday said its consolidated net profit for the quarter ended September 30 was down by over 35 per cent to Rs 117.7 crore against Rs 181. 6 crore in the same quarter last fiscal.
The city-based rug maker in a press release said the company recorded consolidated total revenue of Rs 518.9 Crore for the second quarter against Rs 583.50 Crore for the same period last year.
"The decline in revenues and profits compared to the same period last year is primarily due to the anticipated drop in oseltamivir product sales in the USA and Hep C sales in India," it said.
The Board of Directors has recommended second interim dividend of Rs 1.00 per equity share of Rs 2.00 each.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app